Rankia Colombia Rankia Argentina Rankia Brasil Rankia Chile Rankia Czechia Rankia Deutschland Rankia España Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
14.223 / 16.979
#113779

Re: Farmas USA

Jooe, pues muchas gracias , importante para mi que tenia en plan hacer una comprar al abrir.. Ojala no me den sustos el viernes de brujas , ya vera 

#113780

Re: Farmas USA

Publicación..hala, te quito el pumpeo Mr_Simpson :-)

 

https://finance.yahoo.com/news/trevena-announces-publication-apollo-1-110000935.html

 

Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain

 

Study Summary and Key Findings:

  • In APOLLO-1, a Phase 3 clinical study, 389 patients were administered either oliceridine (TRV130), morphine or placebo intravenously (IV) for 48 hours following bunionectomy.
     
  • There were 3 dosing regimens for oliceridine (0.1mg, 0.35mg, and 0.5mg) and one for morphine (1mg), each self-administered by the patient as needed to control their pain.
     
  • Findings showed that the onset of analgesia for oliceridine was rapid and the proportion of treatment responders in the two higher oliceridine dosing regimens was similar to patients receiving morphine. 
     
  • The most commonly reported adverse effects (AEs) were nausea, vomiting, headache, and dizziness.  Fewer patients receiving oliceridine discontinued treatment due to an AE than patients receiving morphine.  
     
  • Efficacy, safety, and tolerability data provide important context for evaluating the benefit/risk profile of IV oliceridine compared to morphine, and suggest that oliceridine may provide an important treatment option for the management of patients experiencing moderate-to-severe acute pain.

 

Trevena

#113781

Re: Farmas USA

AXGT   2.19 +0.71 (+47.973) Pre-Market: 

esta es la decis que vende humos pero... si da doblones, ahi estoy 

https://finance.yahoo.com/news/axovant-reports-positive-interim-results-103000503.html

  • 25-point (42%) mean improvement in the UPDRS Part III (motor) OFF score, with individual patient improvements of 14-points and 36-points respectively
  • Benefit seen across all UPDRS OFF subscales at 3 months
  • Reductions in ON state dyskinesias seen on the Rush Dyskinesia Rating Scale and diary ON time with dyskinesia
  • Generally well-tolerated with no serious adverse events at 3 months
  • First patient in second cohort expected to be dosed in Q2 2019
  • Axovant to present at the Cowen and Company 39th Annual Health Care Conference on March 11th at 12:00 PM (Eastern Time)

Axovant Reports Positive Interim Results From First Cohort Of SUNRISE-PD Phase 2 Trial Of AXO-Lenti-PD Gene Therapy In Parkinson’s Disease

 

#113782

Re: Farmas USA

TGTX

Fuera a 6.60  +5% haber si las cogemos un poquito más baratas otra vez,,,

#113783

Re: Farmas USA

SGMO

Más cromos a 9.70  promedio 9.93

#113784

Re: Farmas USA

TGTX
He hecho exactamente lo mismo, jeje. Vendidas las del viernes para un 5%.

Brokers destacados